Blog

Two people sit in chairs facing each other, reviewing a document together in a home office setting.
By Ashley Keays March 31, 2026
For most patients, the insurance approval process for TMS is a black box. You submit information, wait, and eventually hear yes or no - often without a clear understanding of what happened in between or why the decision went the way it did. That lack of visibility is a problem because what happens behind the scenes matters. A well-prepared prior authorization submission significantly improves the likelihood of approval. A poorly documented one - or one that misses a specific insurer’s criteria - can result in a denial that takes weeks to appeal, delaying treatment the patient genuinely needs. Why TMS Requires Prior Authorization TMS is an FDA-approved treatment, but FDA approval and insurance coverage are entirely separate things. Insurers make their own coverage determinations based on their own clinical policies, which vary by provider and are updated periodically as the evidence base evolves. Most major insurers in Washington now cover TMS for treatment-resistant major depressive disorder, but they require prior authorization - a formal request from the treating clinic that demonstrates the patient meets their specific eligibility criteria before treatment begins. This is standard for any high-cost or specialist treatment, not unique to TMS. The keyword is “before.” Starting treatment without authorization in place is a significant financial risk. If coverage is denied after treatment has begun, the patient may be liable for the full cost. A clinic that allows this to happen is not doing its job. What Insurers Typically Require Each insurer has its own coverage policy, but most share a common set of core requirements. Understanding these in advance helps you arrive at your evaluation with the right history documented. Diagnosis T MS is covered fo r major depressive dis order (MDD) and, with some insurers, OCD . The diagnosis must be formally documented by a qualified clinician. Off-label uses - anxiety, PTSD, and others - are generally not covered, though this varies and is worth checking with your specific insurer. Prior medication trials Most insurers require documented evidence that the patient has tried and failed to respond to a minimum number of antidepressants - typically two to four, from different drug classes, at adequate doses and durations. “Failed to respond” means either no meaningful improvement or side effects that made the medication intolerable. This documentation needs to be specific: drug names, doses, duration, and outcome. Symptom severity Insurers typically require evidence of moderate to severe depression, usually demonstrated through a validated rating scale score. This is part of why the clinical evaluation matters - it generates the baseline data that supports the authorization request. Prior psychotherapy Some insurers also require documented evidence of prior psychotherapy, typically a course of CBT or equivalent. This requirement is not universal, but it appears in enough coverage policies that it is worth checking early. Medical necessity statement The treating clinician must provide a written statement explaining why TMS is medically necessary for this specific patient, given their history and current presentation. Vague or generic statements are a common reason for denials. The documentation needs to tell a clear, specific clinical story.
A person in a red shirt sits on a gray chair in a waiting area, reading a yellow folder, with a table and rug nearby.
By Ashley Keays March 31, 2026
TMS is often described as a standalone treatment - and it can be. But the research, and clinical experience, point consistently in the same direction: patients who combine TMS with evidence-based therapy tend to do better. Not marginally better. Meaningfully better, with stronger outcomes and longer-lasting results. This article explains why that is, how CBT and ERP specifically complement what TMS does neurologically, and how care coordination works in practice when you’re receiving both treatments - whether from Creative Wellness directly or from an external therapy provider. Why TMS and Therapy Target Different Things TMS works by delivering magnetic pulses to specific areas of the brain involved in mood regulation. For depression, the primary target is the left dorsolateral prefrontal cortex - a region that is typically underactive in people with major depressive disorder. Repeated stimulation over a course of treatment helps restore more normal activity patterns in these neural circuits. What TMS does not do is change how you think. It does not teach coping skills, restructure unhelpful thought patterns, or help you process experiences that may be contributing to your symptoms. That is what therapy does. This is not a limitation of TMS - it is simply a different mechanism. The two approaches address different dimensions of the same condition. TMS creates the neurological conditions for improvement; therapy builds the cognitive and behavioural skills to sustain it. Used together, each makes the other more effective. What Is CBT and Why Does It Pair Well With TMS? Cognitive Behavioural Therapy (CBT) is one of the most extensively researched psychological treatments available. It is based on the principle that thoughts, feelings, and behaviours are interconnected - and that changing unhelpful thought patterns can directly improve mood and reduce symptoms. In practice, CBT helps patients identify automatic negative thoughts (such as catastrophising, black-and-white thinking, or self-blame), examine their accuracy, and replace them with more balanced, realistic perspectives. It also addresses behavioural patterns - particularly avoidance and withdrawal - that tend to maintain and deepen depression. The pairing with TMS is logical. TMS can lift the neurological floor - reducing the severity of depressive symptoms enough for a patient to engage meaningfully in therapy. Many patients find that CBT feels impossible when they are at their lowest; the cognitive effort required is simply too great. TMS can change that. As brain activity normalises, the capacity to engage with and benefit from therapy increases. Conversely, the insights and skills developed in CBT help protect the gains made through TMS. Depression tends to recur, and one of the strongest predictors of relapse is the absence of coping skills when symptoms begin to return . CBT directly addresses this vulnerability.
Two people in casual attire sitting in a small room for a consultation, one on a couch and the other in a chair.
By Ashley Keays March 31, 2026
Finding the right antidepressant is, for many people, a frustrating process of trial and error. You try a medication, wait four to six weeks to assess whether it’s working, adjust the dose, manage side effects, and if it doesn’t work, start again with something else. For patients with treatment-resistant depression, this cycle can stretch across years. Pharmacogenetic testing - genetic testing applied to medication selection - is one of the more meaningful advances in psychiatric care precisely because it addresses this problem directly. At Creative Wellness TMS, we offer genetic testing as part of our integrated approach to treatment planning. This article explains what it is, how it works, and when it’s most useful alongside TMS and medication management. What Is Pharmacogenetic Testing? Pharmacogenetics is the study of how your genes affect your response to drugs. The same medication at the same dose can produce very different outcomes in different people - some respond well, some experience significant side effects , and some metabolize the drug so quickly or slowly that it never reaches a therapeutic level in the body. These differences are largely genetic. Variations in specific genes - particularly those governing liver enzymes responsible for drug metabolism - determine how your body processes psychiatric medications. By analyzing these genes, clinicians can make more informed decisions about which medications are likely to work for you, which are likely to cause problems, and at what dose. At Creative Wellness, the test examines 18 genes relevant to psychiatric medication response. It is completed across two appointments: a sample is collected at the first session, and results are reviewed with your clinician approximately two weeks later. Learn More: Genetic Testing Explained: Why We Offer It & What It Changes What the Results Actually Tell Your Clinician Genetic test results are typically presented in categories that reflect how your body is likely to process specific medications: Poor metabolizers process a drug more slowly than average, meaning standard doses can accumulate to levels that cause side effects. Rapid or ultrarapid metabolizers clear the drug too quickly for it to reach effective concentrations, which can explain why a medication appears not to work even at standard doses. Normal metabolizers fall within the expected range, meaning standard prescribing guidelines apply. This information is applied across the main classes of psychiatric medication - SSRIs, SNRIs, tricyclics, antipsychotics, mood stabilizers, and others. It tells your clinician which drugs from each class are likely to be well-tolerated and effective, which to approach with caution, and which to avoid. It is worth being clear about what the test does not do: it does not predict with certainty that a specific medication will work. Genetics is one factor among several - diagnosis, symptom profile, lifestyle, and other medications all play a role. But it substantially narrows the field and gives prescribing decisions a more solid foundation than symptom history alone.
A medical professional in a lab coat sits at a small table, typing on a laptop and looking at the screen.
By Ashley Keays March 30, 2026
If you’re considering TMS therapy, one of the first questions you probably have is: “Will I actually qualify?” The answer depends on a structured clinical evaluation - a process that goes well beyond a simple checklist. At Creative Wellness TMS, our clinicians assess multiple dimensions of your health history and current symptoms before recommending TMS. This article walks you through exactly what that evaluation involves, so you arrive at your first consultation fully informed. Why the Evaluation Matters TMS is not a one-size-fits-all treatment. It is FDA-approved for specific conditions, requires a meaningful time commitment (typically five sessions per week for four to six weeks) , and carries contraindications for certain patients. The evaluation exists to protect you - ensuring TMS is both safe and likely to be effective given your individual situation. Skipping or rushing this process would be a disservice. A thorough evaluation is what separates a treatment plan built around your needs from a generic one . Step 1: Confirming Your Diagnosis and Condition Severity The evaluation begins with a clear picture of your diagnosis. TMS is FDA-approved for: Treatment-resistant major depressive disorder (MDD) in adults Obsessive-compulsive disorder (OCD) Major depressive disorder in adolescents aged 15 and over (via the NeuroStar system, which Creative Wellness uses - the only FDA-cleared TMS device for this age group) TMS can also be offered as an off-label treatment for conditions including anxiety, PTSD, and certain neurological presentations . In these cases, your clinician will discuss the current evidence base with you and set realistic expectations around outcomes and insurance coverage. Symptom severity is assessed using standardized clinical tools. For depression, this typically involves validated rating scales that measure how significantly your symptoms are affecting your daily life - your sleep, concentration, mood, energy, and ability to function at work or in relationships. This baseline measurement also serves as a reference point for tracking your progress once treatment begins.
A professional sitting at a desk consults with a patient, holding a colorful informational brochure.
By Ashley Keays March 30, 2026
Transcranial magnetic stimulation (TMS) is a proven, FDA-approved treatment for conditions like treatment-resistant depression and OCD - and for many patients, a single course of TMS delivers meaningful, lasting relief. But for others, the journey looks a little different. Some patients benefit from a second course of TMS, periodic booster sessions, or an ongoing maintenance plan to sustain their results over time. If you've completed TMS and are wondering what comes next - or if your clinician has mentioned the possibility of additional treatment - this guide will help you understand why repeat courses happen, how decisions about further treatment are made, and what maintenance TMS can look like in practice. What Is a TMS Course, and How Does It Typically Work? A standard course of TMS at Creative Wellness typically involves daily sessions, five days a week, over four to six weeks. Each session lasts approximately 20 minutes. During treatment, magnetic pulses are precisely delivered to areas of the brain associated with mood regulation, gradually encouraging healthier neural activity. Many patients begin noticing improvements within the first few weeks, and results often continue to develop after the course concludes. For a significant proportion of patients, this initial course produces sustained symptom relief - sometimes for a year or more. However, TMS is not a one-size-fits-all treatment. The brain is complex, mental health conditions vary enormously between individuals, and factors like the severity of symptoms, prior treatment history, and the presence of other conditions all influence how someone responds to TMS. Why Some Patients Benefit From More Than One Course The need for additional TMS treatment doesn't mean the first course failed - in most cases, it means the opposite. Here are the most common reasons a patient might return for further TMS: 1. Symptom Recurrence Over Time C onditions like treatment-resistant depression are chronic for many people . Even when TMS produces an excellent initial response, symptoms can return over time - particularly during periods of heightened stress, major life changes, or seasonal shifts. This is not unique to TMS; it reflects the nature of the underlying condition. In these cases, a repeat course of TMS can effectively re-establish the neural changes that reduced symptoms in the first place. Research suggests that patients who have responded well to TMS previously are likely to respond well again. 2. Partial Response to the Initial Course Some patients experience meaningful improvement during their first TMS course but don't achieve full remission. This partial response is still clinically significant - and it often means the brain is showing signs of neuroplasticity that a second course can build upon. In these situations, a clinician may recommend adjusting the treatment protocol — including targeting different brain regions, modifying the frequency or intensity of pulses, or extending the overall course length — to optimize outcomes. 3. Complex or Comorbid Conditions Patients managing multiple mental health conditions - such as depression alongside PTSD, OCD, or anxiety - often have more complex treatment needs. TMS may need to be applied across different brain regions or protocols to address overlapping symptoms, which can mean a longer or more phased treatment journey. 4. Medication Changes or Life Stressors Significant changes to a medication regimen, a major health event, or a sustained period of stress can sometimes destabilize progress. TMS can play a stabilizing role during these periods, either through a short booster series or a more structured maintenance plan.
Four people talk around a desk in an office with a brick wall, focusing on a laptop screen and a desktop monitor.
By Ashley Keays March 30, 2026
Quick overview When you begin Transcranial Magnetic Stimulation (TMS), one of the most important steps is motor-threshold mapping. Mapping is a quick, clinician-led procedure that measures how your brain responds to single magnetic pulses and uses that information to set a safe, personalized stimulation dose. Because TMS effectiveness and safety depend on correct dosing and placement, mapping is a cornerstone of MD-led TMS care at Creative Wellness. What is motor-threshold mapping? Motor-threshold mapping determines the smallest amount of magnetic energy needed to reliably produce a measurable motor response in a target muscle (usually a thumb or finger). That value - the motor threshold - tells clinicians how excitable the motor cortex is for a specific patient. The clinic then prescribes treatment intensity as a percentage of that threshold, so the therapeutic pulses are individualized rather than “one size fits all.” In practice, mapping is a physiologic test: the clinician delivers single TMS pulses over the motor cortex and observes or records the resulting muscle twitch or electrical signal. The result is an objective number that guides dosing and placement across the rest of the treatment. Mapping is both a safety and efficacy tool. What clinicians measure Motor response - the clinician looks for a consistent muscle twitch (typically in the hand/thumb) in response to single magnetic pulses. Some clinics use surface electromyography (EMG) to record muscle responses; others observe the twitch visually. Resting motor threshold (RMT) - the lowest stimulation intensity that produces a motor response a defined percentage of the time (a reproducible, clinic-defined threshold). RMT is the standard measure used to normalize the dose. Scalp coordinates - mapping also helps identify the motor cortex location relative to the patient’s scalp so clinicians can localize the treatment target ( for depression, typically the left dorsolateral prefrontal cortex ) with greater precision. How mapping determines treatment intensity Mapping converts a physiologic measurement (the motor threshold) into a personalized treatment dose. Treatment protocols are expressed as a percentage of the motor threshold - for example, a protocol may prescribe stimulation at a set percentage above RMT. By tying the dose to each patient’s threshold, clinicians ensure the brain receives effective, but not excessive, stimulation. Two practical benefits of this approach: Safety : By using an individualized threshold, clinicians reduce the chance of overstimulation, which helps minimize rare adverse events (for example, seizures) and other side effects. Effectiveness : Personalized dose improves the likelihood that the targeted brain region receives an adequate stimulation dose to produce meaningful changes in neural networks. Proper placement and dose together improve clinical outcomes over scalp-based “fixed” dosing methods.
More Posts